Supplementary Figure S5 from In vivo screening unveils pervasive RNA-binding protein dependencies in leukemic stem cells and identifies ELAVL1 as a therapeutic target

Ana Vujovic; Laura de Rooij; Ava Keyvani Chahi; He Tian Chen; Brian A. Yee; Sampath K. Loganathan; Lina Liu; Derek C.H. Chan; Amanda Tajik; Emily Tsao; Steven Moreira; Pratik Joshi; Joshua Xu; Nicholas Wong; Zaldy Balde; Soheil Jahangiri; Sasan Zandi; Stefan Aigner; John E. Dick; Mark D. Minden; Daniel Schramek; G Yeo; Kristin J. Hope

doi:10.1158/2643-3230.27024902.v1

Abstract

Supplemental Figure S5 shows the effects of DHTS treatment on THP-1 and human primary AML cells in vitro, the effects of MS-444 treatment on human umbilical cord blood in vivo, and validation of ELAVL1 overexpression by western blot.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vujovic et al. (2024) studied this question.

synapsesocial.com/papers/68e587eeb6db643587523b24 https://doi.org/10.1158/2643-3230.27024902.v1

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S5 from In vivo screening unveils pervasive RNA-binding protein dependencies in leukemic stem cells and identifies ELAVL1 as a therapeutic target

Abstract

Discussion

Cite This Study

Supplementary Figure S5 from In vivo screening unveils pervasive RNA-binding protein dependencies in leukemic stem cells and identifies ELAVL1 as a therapeutic target

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers